Biogen Inc (BIIB)

Index:

Nasdaq 100

$ 132.31
   
  • Change Today:
    $-0.75
  • 52 Week High: $236.72
  • 52 Week Low: $118.84
  • Currency: US Dollars
  • Shares Issued: 145.80m
  • Volume: 119
  • Market Cap: $19,291m
  • RiskGrade: 259

Biogen Inc Overview

In November 2003, Biogen and IDEC Pharmaceuticals finalised their $6bn merger, creating Biogen Idec, the third-largest biotechnology company in the world. The company is now a global leader in the development, manufacturing, and commercialisation of novel therapies. Its major products include treatments for relapsing multiple sclerosis, certain B-cell non-Hodgkin's lymphomas and adult patients with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.

Listings

Index: S&P 500Nasdaq 100Nasdaq CompositeS&P 100
ISIN: US09062X1037

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Biogen Inc Market Data

Currency US Dollars
Share Price $ 132.31
Change Today $ -0.75
% Change -0.56 %
52 Week High $236.72
52 Week Low $118.84
Volume 119
Shares Issued 145.80m
Market Cap $19,291m
RiskGrade 259

What The Brokers Say

Strong Buy 6
Buy 8
Neutral 21
Sell 0
Strong Sell 0
Total 35
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Trades for 12-Jun-2025

Time Volume / Share Price
16:00 151,906 @ $132.31
15:59 100 @ $132.32
15:59 100 @ $132.32
15:59 100 @ $132.29
15:59 100 @ $132.27

Top of Page